BEGIN:VCALENDAR VERSION:2.0 PRODID:-//Talks.cam//talks.cam.ac.uk// X-WR-CALNAME:Talks.cam BEGIN:VEVENT SUMMARY:Beating Malaria – London 2014 - EuroSciCon DTSTART:20140701T080000Z DTEND:20140701T160000Z UID:TALK51158@talks.cam.ac.uk CONTACT:Speaker to be confirmed DESCRIPTION:This three day event will discuss aspects of Malaria control\, infection and treatment in an informal academic setting. This year there are three main topics for discussion\n\n*Vector Control:* Research\, Econo mics and Policy \n*Immunology and Vaccination* \n*Malaria Drug Development and Resistance Control* \n\nWith plenty of opportunity for networking an d debate\, this informal international meeting will bring you up to date with current research and thinking regarding Malaria.\n \nThis event has CPD accreditation and an open oral and poster session. \nhttp://www.regon line.co.uk/Malaria2014\n\nAbstracts can be submitted on any subject relate d to Malaria \n\nThe Deadline for abstract submissions for oral presentati on is April 10th 2014. Abstracts for poster presentation only can be submi tted up to two weeks before the event\n.\nYou can download the instruction s for authors at www.euroscicon.com/ABSTRACTSUBMISSIONS.pdf\nWho Should A ttend: Member of Research Institutions\, Government bodies\, NGOs\, Intern ational Organizations and Academies and Pharmaceutical R and D\n\n*Program Outline*\nDay 1: Vector Control: Research\, Economics and Policy \nThe WH O estimations on the burden of malaria do not fully reflect the availabili ty of new tools to fight the diseases nor the multiplicity of parasitologi cal\, epidemiology and treatment research- as well as the new thinking on financing- that have been taken place in the last decade. In fact 219 mill ion cases of malaria occur every year around the world and 660.000 people still die - mainly in children under the age of 5. Moreover\, it is evide nt that current funding levels do not allow for full implementation of the newest and most effective interventions globally: The Roll Back Malaria P artnership estimates that an annual funding gap of about $2.8 billion will need to be filled in order to to reduce its incidence by 75% and malaria deaths to zero by 2015. This session aims at understanding the scientifi c\, economic and political implications behind the opportunities and hurdl es to stop this killing disease and to achieve the Millennium Development Goals targets. \n\nDay 2: Immunology and Vaccination\nThis session will d iscuss the mechanisms of immunity and immunopathology in order to facilita te vaccine design and the identification of additional therapies for treat ment of severe malaria. There will be plenty of opportunities for debate a nd networking.\n\nDay 3: Drug Development and Resistance Control\nThe pre vention of anti-malarial drug resistance is of enormous public health impo rtance. It can be assumed that no therapy currently under development or t o be developed in the foreseeable future will be totally protective agains t malaria. This session will discuss the development of new treatments fo r malaria together with the use of current drugs to limit\, insofar as it is possible\, any further development of resistance. There will be plenty of opportunity for delegates to present their work and network in an infor mal atmosphere\, with a lot of time given for discussion and debate.\n\n*T alks include*\nPossible new controlling measures for the pyrethroid-resist ant malaria vectors\, Dr Hitoshi Kawada\, Associate Professor\, Institute of Tropical Medicine\, Nagasaki University\, Japan\n\nDevelopment of enant iomerically pure aminoalcohol quinoline derivatives to improve their antim alarial efficiency and assessment of their activity against Plasmodium fal ciparum in combination with dihydroartemisinin\, Dr Catherine Mullié\, As sistant Professor\, Faculté de Pharmacie\, Université de Picardie Jules Verne\, France\n\nFast tracking antimalarial drug discovery through reposi tioning\, Nirmalan Niroshini\, University of Salford\, Manchester\, UK\n\n TAntibody longevity to malaria vaccine candidate antigens in immuno-epidem iology studies. Dr Freya Fowkes\, Head of Malaria and Infectious Disease E pidemiology\, Burnet Institute\, Australia\n\nAvailability and Affordabili ty of Arthemisinin Combination Therapies: do the subsidies work?\, Miss Gi ulia Boselli\, Global Health Specialist- Consultant\, UK\n\nMalaria contro l in coastal areas - special research and policy needs\, Professor Ranjan Ramasamy\, Visiting Professor\, University of Jaffna\, Sri Lanka\n\nAntima larials that improve immune response\, Professor José M. Bautista\, Compl utense University of Madrid\, Madrid\, Spain\n\nNatural products as a sour ce of new drugs and/or herbal treatments for Malaria\, Dr Colin Wright\, R eader in Pharmacognosy\, Bradford School of Pharmacy\, University of Bradf ord\, UK\n\nMalaria control: the nutraceutical potential of natural cocoa powder\, Professor Frederick Addai\, Academic Researcher\, University of G hana Medical School\, Ghana\n\nCitrulline: A novel therapeutic for the cer ebral malaria. Dr Irene Gramaglia\, Associate Professor\, La Jolla Infecti ous Disease Institute\, USA\n\nPlatelets do not kill blood-stage Plasmodiu m parasites but function in experimental cerebral malaria pathogenesis. Dr Joyce M. Velez\, Post-doctoral fellow\, La Jolla Infectious Disease Ins titute\, USA\n\n*Additional confirmed speakers include*\nDr Britta Urban\, Liverpool School of Tropical Medicine\, United Kingdom\nDr Pierre Guermon prez\, Center for Molecular and Cellular Biology of Inflammation\, King's College London\, United Kingdom\nDr Glenn McConkey\, Senior Lecturer\, Sch ool of Biology\, University of Leeds\, UK\nDr Mohga Kamal-Yanni\, Senior h ealth & HIV policy advisor\, Oxfam GB\nMr Aditya Jha\, Centre for Cellular and Molecular Biology\, India\nDr Bhargavi Rao\, Honorary Clinical Resear ch Fellow\, Imperial College London\, UK\nProfessor Andrew Taylor-Robinson \, Professor of Immunology/Haematology & Deputy Dean Research | School of Medical & Applied Sciences CQ University Rockhampton\, Queensland\, Austra lia\n\nKeywords: Malaria\,Vector\,Biological Control\, chemical control\,I nsecticide\, tsetse flies\, Habitat Control\, LLIN\, Anopheles\, pyrethroi d\, resistance\, repellent\, Anopheles vectors\, Environmental change\, Ma laria\, Salinity tolerance\, Sea level rise\, malaria\, reseach\, policy\, financing\, medicines\, Vaccine\,Antibody\,Immunology\,Vaccine delivery\, Immunotherapy\, T cells\, Severe malaria\, inflammation\, B cells\, antibo dy responses\,Quinine\, malaria\, Resistance\, Chloroquine\,4-aminoquinolo ne\,Amodiaquine\,Pyrimethamine\,Proguanil\, Mefloquine\,Atovaquone\,combin ation therapies\, Primaquine \, Artemisinin\, Halofantrine\,Doxycycline\ , Clindamycin\, artemisinin\, cryptolepine\,traditional antimalarial plant s\, Antimalarial\, Plasmodial control\, prophylaxis\, Polyphenols\, Mefloq uine derivatives\, stereochemistry\,antimalarial efficacy\, dihydroartemis inin\, combination\, Antimalarial\, Immune response\, Therapy\, Parasitost atic\, Citrulline\, Nitric Oxide\, Severe Malaria\, cerebral malaria\, pla telets\, aspirin\, plasmodium LOCATION:Cineworld: The O2\, Peninsula Square\, London\, SE10 0DX END:VEVENT END:VCALENDAR